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Renal cell carcinoma (RCC) is the most common malignancy of the kidney, arising 
from the cortical tubular epithelium and accounting for 85% of renal cancers. Recent clin-
ical investigations suggested that Ukrain (UK), a semisynthetic derivative of the greater 
celandine alkaloids derivatized with thiotepa, exerts beneficial effects in the treatment 
of several solid tumors, including the RCC. In this study we investigated whether UK 
was able to modulate the malignant phenotype of RCC cells, by analyzing the expres-
sion of proteins involved in tumor progression.
Caki-1, Caki-2, and ACHN cell lines derived from RCC were treated or not (CT) with 
three doses of UK (5, 10 and 20 μM) for 48h. Epithelial-to-mesenchymal transition (EMT) 
markers such as E-cadherin, beta-catenin and vimentin were analyzed by immunofluo-
rescence; matrix metalloproteinase (MMP)-2 and -9 activity was analyzed by SDS-zymog-
raphy. Intracellular and secreted levels of Secreted Protein Acidic and Rich in Cysteine 
(SPARC) were determined by Western blot, and cell cycle analysis by flow cytometry.
UK was not able to induce E-cadherin and beta-catenin immunoreactivity on cell 
membrane as well as to modify vimentin distribution. By contrast, MMP-2 activity was 
significantly down-regulated after 20 μM UK administration in all cell lines; a simi-
lar pattern was observed for MMP-9 activity in Caki-1, whereas in Caki-2 and ACHN 
MMP-9 decrease was not statistically significant. Since both MMP-2 and MMP-9 seem 
to be engaged in the promotion and progression of RCC, their down-regulation in UK-
treated cells suggests that the drug may modulate the invasive potential of RCC. 
The overall pattern of SPARC expression shows that UK is able to strongly down-reg-
ulate its secretion in cell supernatants at all UK doses in Caki-2, and at 20 μM UK in Caki-1 
and ACHN cells, suggesting that UK may also inhibit extracellular matrix remodeling of 
the tumor microenvironment, possibly rendering tumor microenvironment less permis-
sive for tumor invasion. At the same time, an up-regulation of intracellular SPARC protein 
levels was observed in Caki-1 and ACHN (p ns), and in Caki-2 cells (p<0.05 for CT vs 20 
μM UK), suggesting that UK could also affect cell proliferation by cell cycle inhibition, as 
supported by the cell cycle analysis, since SPARC exerts also a role as cell cycle inhibitor.
Considered as a whole, our results suggest that UK may exert some effects on two 
major aspects involved in RCC progression, such as tumor invasion/microenvironment 
remodeling and, possibly, cell proliferation.
